Newsletter - View InhalteNewsletter2023

ID	6727
Newsletter2023	2026-04-21
Element	13113
Info	[Universal 2023] [Teaser] Teaser Nintedanib AL \| Neues Generikum von ALIUD für 21.4. (PS) (13113)
Position	3
html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:6px;padding-top:6px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Neues Generikum von ALIUD</h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px;padding-bottom:0px;"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Seit dem 10. April 2026 ist das Generikum Nintedanib AL in Form von Weichkapseln in den Wirkstärken 100 mg und 150 mg für Apotheken verfügbar.</p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Angewendet wird das Präparat in Kombination mit Docetaxel zur Behandlung von erwachsenen Patientinnen und Patienten mit lokal fortgeschrittenem, metastasiertem oder lokal rezidivierendem nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Adenokarzinom-Histologie nach Erstlinienchemotherapie.</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><img class="adapt-img" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2026q2/newsletter_2026-04-08_g4.jpg"></td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© ALIUD PHARMA GmbH</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Nintedanib AL Weichkapseln ist in zahlreichen Open-House-Verträgen vertreten und kann daher als Rabattarzneimittel an viele gesetzlich Versicherte abgegeben werden.</p> </td> </tr> <tr> <td align="center" style="Margin:0; padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a target="_blank" href="https://fachwelt.aliud.de/produkte/nintedanib-al" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Weitere Informationen zum Produkt</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">» <a href="https://www.deutschesapothekenportal.de/newsletter/2026q2/pt_nintedanib-al.pdf" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:11px;color:#005CA9;word-break:break-all;">Pflichttext (PDF)</a></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>

Newsletter2023

2026-04-21

Info

[Universal 2023] [Teaser] Teaser Nintedanib AL | Neues Generikum von ALIUD für 21.4. (PS) (13113)

html

<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important">
  <tbody>
    <tr>
      <td align="center" style="padding:0;Margin:0">
        <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center">
          <tbody>
            <tr>
              <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px">
                <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px">
                  <tbody>
                    <tr>
                      <td valign="top" align="center" style="padding:0;Margin:0;width:660px">
                        <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff">
                          <tbody>
                            
                            <tr>
                                <td align="right" style="padding:0;Margin:0;padding-bottom:6px;padding-top:6px;padding-right:0;padding-left:20px;background-color: #e0e0e0;">
                                    <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p>
                                </td>
                            </tr>
  
                            <tr>
                                <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px">
                                    <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Neues Generikum von ALIUD</h2>
                                </td>
                            </tr>
  
                            <tr>
                                <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px;padding-bottom:0px;">
                                    <!--[if mso]>
                                    <table style="width:660px" cellpadding="0" cellspacing="0">
                                        <tr>
                                            <td style="width:340px" valign="top">
                                                <![endif]-->
                                                <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left">
                                                    <tbody>
                                                        <tr>
                                                            <td align="left" style="padding:0;Margin:0;width:340px">
                                                                <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff">
                                                                    <tbody>
                                                                        <tr>
                                                                            <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;">
                                                                                <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Seit dem 10.&nbsp;April 2026 ist das Generikum Nintedanib&nbsp;AL in Form von Weich&shy;kapseln in den Wirk&shy;stärken 100&nbsp;mg und 150&nbsp;mg für Apo&shy;theken verfüg&shy;bar.</p>
                                                                            </td>
                                                                        </tr>
                                                                        <tr>
                                                                            <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;">
                                                                                <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Ange&shy;wendet wird das Präparat in Kombi&shy;nation mit Docetaxel zur Behand&shy;lung von erwachsenen Patien&shy;tinnen und Patienten mit lokal fortge&shy;schrittenem, meta&shy;stasiertem oder lokal rezidivierendem nicht-klein&shy;zelligem Lungen&shy;karzinom (NSCLC) mit Adeno&shy;karzinom-Histologie nach Erst&shy;linien&shy;chemo&shy;therapie.</p>
                                                                            </td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                                <!--[if mso]>
                                            </td>
                                            <td style="width:20px"></td>
                                            <td style="width:320px" valign="top">
                                                <![endif]-->
                                                <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right">
                                                    <tbody>
                                                        <tr>
                                                            <td align="left" style="padding:0;Margin:0;width:320px">
                                                                <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff">
                                                                    <tbody>
                                                                        <tr>
                                                                            <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><img class="adapt-img" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2026q2/newsletter_2026-04-08_g4.jpg"></td>
                                                                        </tr>
                                                                        <tr>
                                                                            <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px">
                                                                                <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© ALIUD PHARMA GmbH</p>
                                                                            </td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                                <!--[if mso]>
                                            </td>
                                        </tr>
                                    </table>
                                    <![endif]-->
                                </td>
                            </tr>
  
                            <tr>
                                <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px">
                                    <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Nintedanib&nbsp;AL Weich&shy;kapseln ist in zahl&shy;reichen Open-House-Verträgen vertreten und kann daher als Rabatt&shy;arznei&shy;mittel an viele gesetzlich Versicherte abge&shy;geben werden.</p>
                                </td>
                            </tr>
  
                            <tr>
                                <td align="center" style="Margin:0; padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:20px;">
                                    <table role="presentation" border="0" cellspacing="0" cellpadding="0">
                                        <tbody>
                                            <tr>
                                                <td align="center" style="border-radius: 0px;" bgcolor="#005CA9">
                                                    <a target="_blank" href="https://fachwelt.aliud.de/produkte/nintedanib-al" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Weitere Informationen zum Produkt</a>
                                                </td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </td>
                            </tr>
  
                            <tr>
                                <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0">
                                    <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px">
                                        <tbody>
                                            <tr>
                                                <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </td>
                            </tr>
  
                            <tr>
                                <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:10px;">
                                    <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">»&nbsp;<a href="https://www.deutschesapothekenportal.de/newsletter/2026q2/pt_nintedanib-al.pdf" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:11px;color:#005CA9;word-break:break-all;">Pflichttext (PDF)</a></p>
                                </td>
                            </tr>
  
                          </tbody>
                        </table>
                      </td>
                    </tr>
                  </tbody>
                </table>
              </td>
            </tr>
          </tbody>
        </table>
      </td>
    </tr>
  </tbody>
</table>

View InhalteNewsletter2023 #6727